tiprankstipranks
Adaptimmune Therapeutics (ADAPY)
OTHER OTC:ADAPY
US Market
ADAPY
Adaptimmune Therapeutics
RESEARCH TOOLSreports
Want to see ADAPY full AI Analyst Report?

Adaptimmune Therapeutics (ADAPY) Financial Statements

1,254 Followers

Adaptimmune Therapeutics Financial Overview

Adaptimmune Therapeutics's market cap is currently $10.52M. The company's EPS TTM is $-0.669; its P/E ratio is -0.10; Adaptimmune Therapeutics is scheduled to report earnings on May 20, 2026, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
Dec 24Dec 23Dec 22Dec 21Dec 20
Income Statement
Total Revenue$ 178.03M$ 60.28M$ 27.15M$ 6.15M$ 3.96M
Gross Profit$ 177.96M$ 50.42M$ -100.58M$ -104.94M$ -87.61M
Operating Income$ -68.76M$ -138.04M$ -163.97M$ -162.25M$ -133.41M
EBITDA$ -52.66M$ -128.20M$ -155.59M$ -155.68M$ -125.81M
Net Income$ -70.81M$ -113.87M$ -165.46M$ -158.09M$ -130.09M
Balance Sheet
Cash & Short-Term Investments$ 151.60M$ 146.94M$ 204.60M$ 369.58M$ 368.22M
Total Assets$ 245.96M$ 282.62M$ 328.92M$ 469.55M$ 451.14M
Total Debt$ 74.21M$ 25.23M$ 23.08M$ 25.47M$ 23.71M
Net Debt$ -16.93M$ -118.76M$ -84.96M$ -124.48M$ -33.17M
Total Liabilities$ 234.11M$ 243.10M$ 247.04M$ 263.58M$ 109.92M
Stockholders' Equity$ 11.85M$ 39.51M$ 81.88M$ 205.96M$ 341.23M
Cash Flow
Free Cash Flow$ -75.93M$ -145.76M$ -171.51M$ 1.95M$ -56.50M
Operating Cash Flow$ -73.21M$ -140.88M$ -141.77M$ 10.73M$ -53.59M
Investing Cash Flow$ -58.95M$ 176.54M$ 89.14M$ 75.80M$ -278.92M
Financing Cash Flow$ 78.75M$ 880.00K$ 12.87M$ 3.29M$ 340.05M
Currency in USD

Adaptimmune Therapeutics Earnings and Revenue History

Income Statement >

Adaptimmune Therapeutics Debt to Assets

Balance Sheet >

Adaptimmune Therapeutics Cash Flow

Cash Flow >

Adaptimmune Therapeutics Forecast EPS vs Actual EPS

Earnings >